Clinical Development Director
Clermont-Ferrand, 63000, France
NCT Number: NCT01794312
The purpose of this study is to assess the efficacy and safety of T4020 versus vehicle.
Looking for future studies?
Notify Me18 year–95 year
All sexes
Interventional
Phase 3
Clermont-Ferrand, 63000, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Day 28
Reduction in neurotrophic ulcer/keratitis area of 50% or more
Time frame: From the first visit to the final visit performed by the patient + 1 month later, assessed up to 71 days
With at least one TEAE
Time frame: Baseline and Day 28
Change from baseline in far best-corrected visual acuity (LogMAR) in the pathologic eye
Laboratoires Thea
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01756456
Corneal Diseases, Corneal Ulcer
Dijon, France
View Trial DetailsNCT02293876
Corneal Diseases, Corneal Ulcer
Belo Horizonte, Minas Gerais, Brazil
View Trial DetailsNCT04420962
Corneal Diseases, Corneal Ulcer
Ann Arbor, Michigan, United States
View Trial DetailsNCT06229379
Cardiovascular Diseases, Cataract
Guangzhou, Guangdong, China
View Trial Details